The 2.3% device tax is more complex than you realize; Poll: Consumers demand more device safety oversight;

@FierceMedDev: Stryker Stent May Not Be Worth the Stroke Risks, FDA Says via @BloombergNewsItem | Follow @FierceMedDev

> Experts advise medical device companies that implementing the 2.3% excise tax will be more complex than people think. Report

> PA-based ClearCount Medical Solutions has launched a new addition to its radio frequency technology system that prevents surgical sponges and towels from getting left inside a patient. Item

> Kips Bay Medical ($KIPS) has tapped CFO Scott Kellen to also be COO. Kips Bay release

> Meridian Bioscience's ($VIVO) Bioline unit has received clearance from the Therapeutic Goods Administration in Australia for its illumigene Group B Streptococcus test. This approval comes on the heels of the recent FDA clearance. Meridian release

> Medical products company Abbott ($ABT) has named the independent, research-based pharmaceutical company it will spin off by the end of this year: AbbVie. Story

And Finally... Most Americans want strong medical device safety oversight, according to a new Consumer Reports poll. Release

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.